Pamrevlumab and idiopathic pulmonary fibrosis
The Lancet Respiratory Medicine in conversation with
English - September 27, 2019 15:00 - 6 minutes - 4.49 MBLife Sciences Science Education lungs pulmonary smoking vape flu Homepage Download Apple Podcasts Google Podcasts Overcast Castro Pocket Casts RSS feed
Previous Episode: Nicotine patches, e-cigarettes, and smoking cessation
Next Episode: Looking to the future of cystic fibrosis care
Dr. Luca Richeldi discusses a trial looking at pamrevlumab, an anti-connective tissue growth factor therapy for the treatment of idiopathic pulmonary fibrosi
Continue this conversation on social!
Follow us today at...
https://twitter.com/thelancet
https://instagram.com/thelancetgroup
https://facebook.com/thelancetmedicaljournal
https://linkedIn.com/company/the-lancet
https://youtube.com/thelancettv